{"id":59333,"date":"2024-02-28T05:52:45","date_gmt":"2024-02-28T05:52:45","guid":{"rendered":"https:\/\/medsname.com\/torvate\/"},"modified":"2026-04-30T10:23:59","modified_gmt":"2026-04-30T10:23:59","slug":"torvate","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/torvate\/","title":{"rendered":"Torvate"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 \u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u0391\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Torvate (Sodium valproate 200 \/ 300 \/ 500 mg) is an anticonvulsant and mood stabiliser used for epilepsy, bipolar mania, and migraine prophylaxis. Absolute contraindication in pregnancy and women of childbearing potential without strict pregnancy-prevention measures<\/strong> \u2014 high teratogenicity and neurodevelopmental risk.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

Torvate at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a> \u2014 \u03c0\u03b1\u03c1\u03ac\u03b8\u03c5\u03c1\u03bf \u03ac\u03c6\u03b9\u03be\u03b7\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03ae \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c7\u03c9\u03c1\u03af\u03c2 \u03c7\u03c1\u03ad\u03c9\u03c3\u03b7 \u2014 \u03ba\u03b1\u03b9 \u03b4\u03b9\u03ba\u03b1\u03b9\u03bf\u03cd\u03c4\u03b1\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03c3\u03c4\u03bf \u03c0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b1\u03c6\u03bf\u03c3\u03af\u03c9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>. \u0394\u03b9\u03b1\u03c4\u03af\u03b8\u03b5\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c3\u03c4\u03b9\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03c0\u03c1\u03bf\u03bf\u03c1\u03b9\u03c3\u03bc\u03bf\u03cd\u03c2.<\/p>\n

What Torvate is and how it works<\/h2>\n

Torvate is a sodium valproate tablet supplied by Torrent. Available strengths: 200 \/ 300 \/ 500 mg<\/strong>. Valproate is a broad-spectrum anticonvulsant whose anti-seizure mechanisms include sodium-channel blockade, T-type calcium-channel modulation, and increased GABA availability. The anti-manic mechanism is poorly understood but well-evidenced in trials.<\/p>\n

\nPregnancy \u2014 absolute contraindication outside epilepsy<\/strong><\/p>\n

Valproate is one of the most teratogenic medications in routine use.<\/strong> First-trimester exposure produces neural tube defects (~ 1\u20132% absolute risk), cardiac and skeletal malformations, and a substantial reduction in childhood IQ (mean 7\u201310 points lower at age 6). UK MHRA, EMA, and FDA all require strict pregnancy-prevention programmes for women of childbearing potential. Outside refractory epilepsy where no alternative exists, do not initiate or continue valproate in any woman of childbearing potential without effective contraception and a pregnancy-prevention programme<\/strong>. Switch to lithium, lamotrigine, or an atypical antipsychotic for bipolar maintenance in pre-menopausal women.<\/p>\n<\/div>\n

\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/h2>\n\n\n\n\n\n\n\n\n\n
\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\n\u0395\u03ba\u03ba\u03af\u03bd\u03b7\u03c3\u03b7<\/th>\n\u03a3\u03c4\u03cc\u03c7\u03bf\u03c2<\/th>\nTarget level<\/th>\n<\/tr>\n<\/thead>\n
Generalised epilepsy<\/td>\n10\u201315 mg\/kg\/day in 2 doses<\/td>\n20\u201360 mg\/kg\/day<\/td>\n50\u2013100 \u00b5g\/mL<\/td>\n<\/tr>\n
Bipolar mania (acute)<\/td>\n20\u201330 mg\/kg\/day in 2 doses<\/td>\n20\u201360 mg\/kg\/day<\/td>\n50\u2013125 \u00b5g\/mL<\/td>\n<\/tr>\n
Bipolar maintenance<\/td>\n\u2014<\/td>\n500\u20132500 mg\/day<\/td>\n50\u2013100 \u00b5g\/mL<\/td>\n<\/tr>\n
\u03a0\u03c1\u03cc\u03bb\u03b7\u03c8\u03b7 \u03bc\u03b9\u03b3\u03ba\u03c1\u03b1\u03af\u03bd\u03b7\u03c2<\/td>\n250 mg BID<\/td>\n500\u20131500 mg\/day<\/td>\n\u2014<\/td>\n<\/tr>\n
\u0397\u03bb\u03b9\u03ba\u03b9\u03c9\u03bc\u03ad\u03bd\u03bf\u03b9 \/ \u03b1\u03bd\u03b7\u03c3\u03c5\u03c7\u03af\u03b1 \u03b3\u03b9\u03b1 \u03b7\u03c0\u03b1\u03c4\u03b9\u03ba\u03ae \u03b4\u03c5\u03c3\u03bb\u03b5\u03b9\u03c4\u03bf\u03c5\u03c1\u03b3\u03af\u03b1<\/td>\nhalve dose<\/td>\n\u2014<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b1\u03c3\u03c6\u03b1\u03bb\u03b9\u03c3\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b5\u03ba\u03c4\u03b9\u03bc\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\n\u0397\u03c0\u03b1\u03c4\u03bf\u03c4\u03bf\u03be\u03b9\u03ba\u03cc\u03c4\u03b7\u03c4\u03b1<\/strong><\/p>\n

Idiosyncratic fatal hepatitis is a recognised valproate complication, highest risk in children < 2 years on polytherapy. Mandatory baseline LFTs and recheck at 3 months, 6 months, then yearly. Stop immediately for jaundice, hepatomegaly, RUQ pain, or unexplained AST\/ALT > 3\u00d7 ULN.<\/p>\n<\/div>\n

\nPancreatitis (rare)<\/strong><\/p>\n

Acute haemorrhagic pancreatitis described, including paediatric fatal cases. Stop for unexplained abdominal pain, vomiting, anorexia.<\/p>\n<\/div>\n

\nHyperammonaemia<\/strong><\/p>\n

Valproate inhibits the urea cycle; hyperammonaemia can occur even with normal LFTs and produces drowsiness, confusion, and (rarely) encephalopathy. Check ammonia in patients with new lethargy or cognitive change.<\/p>\n<\/div>\n

\nPolycystic ovary syndrome and metabolic effects<\/strong><\/p>\n

Long-term valproate is associated with weight gain, insulin resistance, and PCOS in young women \u2014 another reason to prefer alternatives in pre-menopausal women.<\/p>\n<\/div>\n

\nThrombocytopenia and platelet dysfunction<\/strong><\/p>\n

Mild thrombocytopenia is common; check FBC at baseline, 3 months, 6 months. Significant thrombocytopenia is rare.<\/p>\n<\/div>\n

\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n